Search results
Showing 1 to 15 of 21 results for denosumab
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence submission was received from Amgen. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA549
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]
In development [GID-TA10071] Expected publication date: TBC
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.
View quality statements for QS149Show all sections
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Discontinued [GID-TAG300]
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued [GID-TAG411]
Evidence-based recommendations on radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.
View recommendations for IPG759Show all sections
children) - omalizumab TA265 Bone metastases from solid tumours - denosumab TA566 Cochlear implant for children and adults with severe...
Radiofrequency ablation for palliation of painful spinal metastases (IPG758)
Evidence-based recommendations on radiofrequency ablation for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.
View recommendations for IPG758Show all sections
Discontinued [GID-TA10072]